Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14599990 | 0.86 | NPY4R (0.38) | — | |
| SCHEMBL7602596 | 0.86 | NPY4R (0.38) | — | |
| SCHEMBL26204935 | 0.84 | — | — | |
| SCHEMBL22013279 | 0.84 | EPHX1 (0.35) | EPHX1 | |
| SCHEMBL21262051 | 0.83 | CHRNB2 (0.32) | — | |
| SCHEMBL23872238 | 0.82 | C3AR1 (0.36) | EPHX1 | |
| SCHEMBL22215553 | 0.82 | C3AR1 (0.36) | EPHX1 | |
| SCHEMBL16231519 | 0.82 | KDM4E (0.48) | FOLH1KDM4EMAPK1HIF1AEPHX1 | |
| SCHEMBL12055210 | 0.82 | KDM4E (0.48) | FOLH1KDM4EMAPK1HIF1AEPHX1 | |
| SCHEMBL22215549 | 0.81 | NPY4R (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170144998-A1 | ELASTASE INHIBITORS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH | 2017-05-25 | — | — | US | disclosed |
| US-9656972-B2 | Compounds for treatment of cystic fibrosis | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160159754-A1 | COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159754-A1 | COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS | CFTR, ELANE, OTC | FOLH1 1386/4885KDM4E 4623/4885MAPK1 4495/4885 |
| US-20170144998-A1 | ELASTASE INHIBITORS | SERPINB1, ELANE, CELA1 | FOLH1 950/4885KDM4E 3860/4885MAPK1 4228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.